SCHEMBL25287060

SCHEMBL25287060

O=C1NC(=O)C(=Cc2cc(-c3ccccc3)ccn2)S1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 2/20 0.55
▸ PIM3 Q86V86 1/20 0.55
▸ PIM2 Q9P1W9 1/20 0.55
▸ PTPN1 P18031 3/20 0.54
▸ HPGD P15428 3/20 0.51
▸ MTOR P42345 3/20 0.50
▸ PIK3CG P48736 3/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NAT1 P18440 1/20 0.50
▸ CISD1 Q9NZ45 3/20 0.49
▸ PIK3CD O00329 2/20 0.49
▸ CSNK2A2 P19784 2/20 0.49
▸ PIK3CA P42336 2/20 0.49
▸ PIK3CB P42338 2/20 0.49
▸ CLK1 P49759 2/20 0.49
▸ DYRK1A Q13627 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ MAOB P27338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25245749 1.00 PIM1 (0.55) PIM1PIM3PIM2PTPN1HPGD
SCHEMBL25287298 0.87 PIM1 (0.58) PIM1PIM2PTPN1HPGDMTOR
SCHEMBL25240455 0.87 PIM1 (0.58) PIM1PIM2PTPN1HPGDMTOR
SCHEMBL25242245 0.84 PIM1 (0.50) PIM1PIM2PTPN1HPGDMTOR
SCHEMBL25289003 0.84 PIM1 (0.65) PIM1PIM2PTPN1MTORPIK3CG
SCHEMBL25282477 0.84 PIM1 (0.50) PIM1PIM2PTPN1HPGDMTOR
SCHEMBL25243743 0.84 PIM1 (0.65) PIM1PIM2PTPN1MTORPIK3CG
SCHEMBL25283980 0.81 PIM1 (0.64) PIM1PIM2PTPN1HPGDPIK3CG
SCHEMBL25245472 0.81 PIM1 (0.64) PIM1PIM2PTPN1HPGDPIK3CG
SCHEMBL1247436 0.80 MTOR (0.64) PIM1PIM3PIM2HPGDMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 — — WO claimed
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 — — US disclosed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 — — EP disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME SREBF1, SREBF2, SP1 PIM1 922/4885PIM3 1802/4885PIM2 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback